Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$104.28 USD

104.28
3,255,521

+3.23 (3.20%)

Updated May 31, 2024 04:00 PM ET

After-Market: $104.80 +0.52 (0.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ILMN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Illumina, Inc. [ILMN]

Reports for Purchase

Showing records 301 - 320 ( 361 total )

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 301

02/25/2013

Company Report

Pages: 11

Updating Model Post Verinata Deal Closure - Introducing Pre-Natal Cheatsheet

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 302

01/29/2013

Company Report

Pages: 10

4Q12 Recap - Robust MiSeq, Consumables & Services Driving 2013 Growth Story

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 303

01/25/2013

Company Report

Pages: 7

4Q12 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 304

01/07/2013

Daily Note

Pages: 8

Acquiring Verinata for $350 MM to Enter NIPT Space

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 305

01/04/2013

Company Report

Pages: 7

Downgrading to NEUTRAL from OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 306

10/24/2012

Company Report

Pages: 10

3Q12 Recap - Survives Relatively Unscathed - Very Strong Instrument Sales

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 307

10/22/2012

Company Report

Pages: 7

3Q12 Preview - Expecting Ok Results - MiSeq Checks Continue to Encourage

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 308

07/25/2012

Company Report

Pages: 11

2Q12 Results Stand Out In an Ugly Week For Tools - Strong Sequencing Consumables Drives Beat - EPS Guidance Upped

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 309

07/22/2012

Company Report

Pages: 7

2Q12 Preview

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 310

06/07/2012

Daily Note

Pages: 5

Termination of Coverage

Provider: AURIGA USA

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 311

06/07/2012

Daily Note

Pages: 7

Channel Checks - 2Q12 Broad Institute Production Appears Flattish Q/Q - More Cautious Near Term on MiSeq Teething Pains - Maintaining LT OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 312

04/24/2012

Company Report

Pages: 5

1Q12 Review: Nice Start to the Year; Reaffirms Guidance; New $250MM Buyback

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 313

04/24/2012

Company Report

Pages: 10

Solid 1Q12 Results, Driven by Strong MiSeq Systems & Robust Sequencing Consumables - Guidance Reaffirmed - Lowering PT to $52 After Roche Snub

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 314

04/23/2012

Company Report

Pages: 7

1Q12 Preview - Expecting Solid Guidance and Commentary Post Positive Preannouncement - Price Target Under Review in the New World Ex-Roche

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 315

04/18/2012

Company Report

Pages: 5

Roche Decides Not To Extend Tender Offer: Fundamentals Move to the Forefront

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 10.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 316

04/10/2012

Company Report

Pages: 6

Adjusting Estimates to Reflect Preannouncement; Roche will Likely go Higher

Provider: AURIGA USA

Analyst: MCDONALD P

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 317

03/30/2012

Daily Note

Pages: 7

Roche Presents to ISS Today Helping Explain Yesterday''s Upped Bid - Keep Eyes Peeled for Presentation Filing By Roche Today - High Hurdle Remains

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 318

03/27/2012

Company Report

Pages: 8

Legal Update Following Conversation with IP Expert

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 319

03/22/2012

Daily Note

Pages: 7

Multi System Order with Macrogen Announced this A.M. - Driving $7+ MM in Rev - Good For Takeout Defense

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: Illumina, Inc.

Industry: Medical - Biomedical and Genetics

Record: 320

03/14/2012

Company Report

Pages: 7

Channel Checks Suggest Positive Reception of MiSeq & More Competitive Sequencing Service Pricing - Maintaining OUTPERFORM.

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party